- Conditions
- Pulmonary; Hypertension, Heart Failure, Preserved Ejection Fraction
- Interventions
- 15N Nitrate, 14N Nitrate
- Drug
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 253
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 6,263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 66
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
- Conditions
- Heart Failure, Diastolic
- Interventions
- Exercise Training
- Other
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Obesity, Heart Failure
- Interventions
- NNC0487-0111, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 206
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
- Conditions
- Cardiovascular Risk, Heart Failure, Chronic Kidney Disease
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Fremont, California • McKinney, Texas
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- TX000045- Dose A, TX000045- Dose B, Placebo
- Drug
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Rate Adaptive Pacing
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Rochester, Minnesota • Kansas City, Missouri • Cincinnati, Ohio + 2 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 0.9% Sodium Chloride, Furosemide 40 mg
- Drug
- Lead sponsor
- Adhish Agarwal
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 87
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 77 more
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
- Interventions
- Beta blocker
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Exercise Tolerance, Dyspnea, Heart Failure, Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Gamification plus social incentive, Gamification plus competition
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
- Interventions
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
- Device
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Diabetes Mellitus, Heart Failure
- Interventions
- Tc99m-Maraciclatide
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Heart Failure, Type 2 Diabetes, Atrial Fibrillation
- Interventions
- Decision Support, Referral
- Behavioral
- Lead sponsor
- American College of Cardiology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Amarillo, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate, Potassium Chloride + Placebo for Empagliflozin
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
- Interventions
- Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cardiac Amyloidosis
- Interventions
- • Cardiac Rehabilitation
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Heart Failure
- Interventions
- Performance of WHEELS-I in promoting DASH/SRD adoption
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 45 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- empagliflozin, Placebo tablet
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois